S&P 500   4,567.45 (+0.28%)
DOW   35,530.90 (+0.32%)
QQQ   391.03 (+0.22%)
AAPL   189.81 (-0.31%)
MSFT   378.03 (-1.22%)
META   333.17 (-1.72%)
GOOGL   135.85 (-0.98%)
AMZN   146.55 (-0.33%)
TSLA   248.37 (+0.67%)
NVDA   480.98 (+0.58%)
NIO   7.23 (+0.28%)
BABA   74.76 (-2.58%)
AMD   124.41 (+1.97%)
T   16.23 (+0.31%)
F   10.63 (+2.51%)
MU   77.00 (+1.16%)
CGC   0.55 (+1.70%)
GE   119.47 (+0.52%)
DIS   92.67 (+0.18%)
AMC   7.03 (+4.93%)
PFE   30.04 (+1.18%)
PYPL   58.64 (+0.29%)
XOM   103.34 (-0.54%)
S&P 500   4,567.45 (+0.28%)
DOW   35,530.90 (+0.32%)
QQQ   391.03 (+0.22%)
AAPL   189.81 (-0.31%)
MSFT   378.03 (-1.22%)
META   333.17 (-1.72%)
GOOGL   135.85 (-0.98%)
AMZN   146.55 (-0.33%)
TSLA   248.37 (+0.67%)
NVDA   480.98 (+0.58%)
NIO   7.23 (+0.28%)
BABA   74.76 (-2.58%)
AMD   124.41 (+1.97%)
T   16.23 (+0.31%)
F   10.63 (+2.51%)
MU   77.00 (+1.16%)
CGC   0.55 (+1.70%)
GE   119.47 (+0.52%)
DIS   92.67 (+0.18%)
AMC   7.03 (+4.93%)
PFE   30.04 (+1.18%)
PYPL   58.64 (+0.29%)
XOM   103.34 (-0.54%)
S&P 500   4,567.45 (+0.28%)
DOW   35,530.90 (+0.32%)
QQQ   391.03 (+0.22%)
AAPL   189.81 (-0.31%)
MSFT   378.03 (-1.22%)
META   333.17 (-1.72%)
GOOGL   135.85 (-0.98%)
AMZN   146.55 (-0.33%)
TSLA   248.37 (+0.67%)
NVDA   480.98 (+0.58%)
NIO   7.23 (+0.28%)
BABA   74.76 (-2.58%)
AMD   124.41 (+1.97%)
T   16.23 (+0.31%)
F   10.63 (+2.51%)
MU   77.00 (+1.16%)
CGC   0.55 (+1.70%)
GE   119.47 (+0.52%)
DIS   92.67 (+0.18%)
AMC   7.03 (+4.93%)
PFE   30.04 (+1.18%)
PYPL   58.64 (+0.29%)
XOM   103.34 (-0.54%)
S&P 500   4,567.45 (+0.28%)
DOW   35,530.90 (+0.32%)
QQQ   391.03 (+0.22%)
AAPL   189.81 (-0.31%)
MSFT   378.03 (-1.22%)
META   333.17 (-1.72%)
GOOGL   135.85 (-0.98%)
AMZN   146.55 (-0.33%)
TSLA   248.37 (+0.67%)
NVDA   480.98 (+0.58%)
NIO   7.23 (+0.28%)
BABA   74.76 (-2.58%)
AMD   124.41 (+1.97%)
T   16.23 (+0.31%)
F   10.63 (+2.51%)
MU   77.00 (+1.16%)
CGC   0.55 (+1.70%)
GE   119.47 (+0.52%)
DIS   92.67 (+0.18%)
AMC   7.03 (+4.93%)
PFE   30.04 (+1.18%)
PYPL   58.64 (+0.29%)
XOM   103.34 (-0.54%)

Orchestra BioMed Stock Price, News & Analysis (NASDAQ:OBIO)

$6.53
+0.02 (+0.31%)
(As of 12:22 PM ET)
Compare
Today's Range
$6.30
$6.62
50-Day Range
$4.42
$10.37
52-Week Range
$4.26
$23.39
Volume
6,244 shs
Average Volume
101,802 shs
Market Capitalization
$233.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.50

Orchestra BioMed MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
168.0% Upside
$17.50 Price Target
Short Interest
Bearish
5.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.14mentions of Orchestra BioMed in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.53) to ($1.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

858th out of 949 stocks

Surgical & Medical Instruments Industry

88th out of 96 stocks


OBIO stock logo

About Orchestra BioMed Stock (NASDAQ:OBIO)

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

OBIO Stock Price History

OBIO Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Orchestra BioMed Holdings, Inc. (OBIO)
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings (OBIO) Gets a Buy from LifeSci Capital
Crude Oil Rises Over 1%; Revance Therapeutics Shares Plummet
Why Shares of Orchestra BioMed Jumped Tuesday
Orchestra, Medtronic Join Forces
Orchestra Biomed Holdings Inc (OBIO)
See More Headlines
Receive OBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchestra BioMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/12/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OBIO
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.50
High Stock Price Target
$20.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+168.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-2,730,000.00
Pretax Margin
-22,322.03%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.23 per share

Miscellaneous

Free Float
N/A
Market Cap
$233.38 million
Optionable
Not Optionable
Beta
-0.18
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. David P. Hochman (Age 48)
    Founder, Chairman of the Board of Directors & CEO
    Comp: $790k
  • Mr. Darren R. Sherman (Age 52)
    Founder, President, COO & Director
    Comp: $790k
  • Mr. Andrew Lawrence Taylor M.B.A. (Age 52)
    Chief Financial Officer
  • Ms. Inessa R. Wheeler
    Vice President of Strategy & Marketing
  • Mr. William Reed Little (Age 52)
    Executive VP of Corporate Development & Strategy
  • Dr. Yuval Hay Mika D.Sc
    Ph.D., GM & CTO of Bioelectronic Therapies
  • Dr. George Papandreou Ph.D.
    Senior VP & GM of Focal Therapies
  • Dr. Hans-Peter Stoll M.D.
    Ph.D., Chief Clinical Officer
  • Dr. J.C. Simeon
    Senior Vice President of Quality
  • Dr. Avraham Matityahu Fischer M.D. (Age 67)
    Senior Vice President of Medical Affairs & Innovation














OBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Orchestra BioMed stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchestra BioMed in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OBIO shares.
View OBIO analyst ratings
or view top-rated stocks.

What is Orchestra BioMed's stock price target for 2024?

3 Wall Street analysts have issued 1-year price targets for Orchestra BioMed's stock. Their OBIO share price targets range from $15.00 to $20.00. On average, they expect the company's stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 168.0% from the stock's current price.
View analysts price targets for OBIO
or view top-rated stocks among Wall Street analysts.

How have OBIO shares performed in 2023?

Orchestra BioMed's stock was trading at $9.12 at the start of the year. Since then, OBIO stock has decreased by 28.4% and is now trading at $6.53.
View the best growth stocks for 2023 here
.

When is Orchestra BioMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our OBIO earnings forecast
.

How were Orchestra BioMed's earnings last quarter?

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) released its earnings results on Monday, November, 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.01. The business earned $0.42 million during the quarter, compared to the consensus estimate of $0.89 million.

Who are Orchestra BioMed's major shareholders?

Orchestra BioMed's stock is owned by a number of institutional and retail investors. Top institutional investors include Charles Schwab Investment Management Inc. (0.43%), Northern Trust Corp (0.40%), TD Asset Management Inc (0.26%), Arkadios Wealth Advisors (0.14%), Bank of New York Mellon Corp (0.11%) and The Manufacturers Life Insurance Company (0.11%).

How do I buy shares of Orchestra BioMed?

Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OBIO) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -